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g-butyrobetaine has long been known as the precursor of endogenous L-carnitine synthesis. In this issue,
Koeth et al. (2014) demonstrate that it is also a major metabolite of L-carnitine degradation by gut bacteria
that precedes the enteric production of trimethylamine and trimethylamine-N-oxide.L-carnitine is a crucial molecule for lipid
metabolism as it enables transport of
activated fatty acids from the cytosol to
the mitochondrial matrix where they are
oxidized to releaseenergy. It hasbeenesti-
mated that the main source of L-carnitine
in omnivorous humans is diet, especially
redmeat, which represents approximately
75%of the daily needswhile the remaining
25% are provided by endogenous syn-
thesis from trimethyllysine (Figure 1) (Vaz
and Wanders, 2002). About 50%–90%
of dietary L-carnitine is absorbed by an
active saturable transport system located
in the upper gastrointestinal tract (i.e.,
duodenum and jejunum). When the
active transport is saturated, L-carnitine
can also be absorbed by passive diffusion,
although it is much less efficient, andmost
of the unabsorbed L-carnitine will travel
further down into the gastrointestinal tract
where it can be metabolized by gut bacte-
ria (Rebouche and Seim, 1998). In recent
studies, L-carnitine has been associated
with atherosclerosis in humans with
high circulating levels of trimethylamine-
N-oxide (TMAO) (Koeth et al., 2013), a
mammalian-microbial cometabolite that
results from the bacterial production of
trimethylamine (TMA) from various amine-
containing molecules (e.g., choline,
betaine, L-carnitine) followed by its oxida-
tion by hepatic flavin mono-oxygenases
(Figure 1). Although the endogenousmeta-
bolismofL-carnitinehasbeen investigated
since the 1980s, only a few works have
explored its catabolism by microbes,
and very little is known about its overall
metabolism by the complex gut micro-
bial ecosystem. In this issue of Cell
Metabolism, Koeth et al. now demonstrate
that L-carnitine is mainly catabolized
by gut microbiota into g-butyrobetaine
(gBB), which can serve as a precursorto form TMA and TMAO (Koeth et al.,
2014).
Koeth et al. (2014) performed most of
the animal work using apolipoprotein E-
deficient (Apoe/) mice that spontane-
ously develop atherosclerotic lesions on
a standard diet. The authors first showed
that ingestion of L-carnitine led to signifi-
cant rises of TMA, TMAO, and gBB in
plasma that was dependent on the
presence of gut microbiota. They further
confirmed in germ-free animals that gBB
was a direct product of L-carnitine in vivo.
Following ingestion of labeled gBB, large
amounts of TMA and TMAO were re-
corded, whereas no choline, betaine, or
dehydrocarnitine could be observed.
This indicates that once gBB has been
produced, it is mainly further metabolized
into TMA/TMAO, although a marginal
production of L-carnitine was also re-
ported, which is consistent with endoge-
nous conversion of gBB to L-carnitine.
Interestingly, using ex vivo cultured intes-
tinal segments that included lumenal con-
tent, the authors also demonstrated that
conversion of L-carnitine to gBB started
in the jejunum to peak in the cecum and
colon, while TMA production arising
from either L-carnitine or gBB degrada-
tion mainly occurred within the cecum
and, to a lesser extent, in the colon. This
suggests a collaborative metabolism of
L-carnitine by several bacterial species
inhabiting different sections of the gut
that are occupied by various microbial
ecosystems. In addition, the authors iden-
tified yeaW/X as a potential enzyme com-
plex that directly transforms L-carnitine
into TMA, which demonstrates that this
direct transformation pathway should
not be overlooked.
The authors then tested the impact of
gBB in the presence or absence of gut mi-Cell Metabolism 20,crobiota on the development of athero-
sclerosis in Apoe/ mice. They found a
significant increase of atherosclerotic le-
sions in animals fed 15 weeks with gBB
compared with those fed the same diet
supplemented with an antibiotic mixture,
indicating that gBB may have a proa-
therogenic effect that requires the pres-
ence of microbes. Finally, based on 16S
sequencing of the gut microbiota, the au-
thors identified a few specific bacterial
groups that were associated with the pro-
duction of gBB from L-carnitine or TMAO
from gBB. This further supports the local-
izedmetabolism of L-carnitine by different
microbes along the gastrointestinal tract.
Hence, Koeth et al. (2014) present here
an interesting study that sheds light on
some aspects of trimethylamine meta-
bolism, paving the way toward a better
understanding of its role in host-microbe
metabolic interactions in the context
of atherosclerosis. Yet many questions
remain to be answered. Most evidence
supporting the proatherosclerotic action
of gBB and TMAO has been derived
from the Apoe/ mouse model, and this
should be confirmed in other models of
atherosclerosis and in humans. Indeed,
TMAO is a major product of seafood con-
sumption as it serves as an osmoprotec-
tant in many fishes. In human studies,
large amounts of TMAO have been found
following ingestion of cod and prawns, 67
and 47 times higher than beef, respec-
tively (Mitchell et al., 2002). Still, high fish
consumption that leads to large circu-
lating levels of TMAO without production
of gBB has never been associated with
increased cardiovascular risk. This sug-
gests complex biological mechanisms
underlying the influence of gBB and
TMAO on atherosclerosis development.
Finally, Koeth et al. emphasize here theNovember 4, 2014 ª2014 Elsevier Inc. 699
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Figure 1. Mammalian-Microbial Cometabolism of L-Carnitine
Dietary L-carnitine is preferentially metabolized by the gut microbiota into g-butyrobetaine (gBB) that is further converted into trimethylamine (TMA). Some bac-
teria can oxidize TMA into trimethylamine-N-oxide (TMAO). TMA can also be derived from themicrobial metabolism of dietary betaine and choline. Both TMA and
TMAO can be degraded by some bacteria into dimethylamine (DMA), methylamine (MA), and finally ammonia (NH3). All of thesemetabolites can be absorbed and
further metabolized endogenously by the liver. Although there is some endogenous synthesis of L-carnitine from trimethyllysine and gBB, this latter metabolite is
largely catabolized into TMA, which is in turn oxidized by flavin mono-oxygenases (FMO) to form TMAO. The methylation pathway is shown here as an illustration
of the relationship between L-carnitine/gBB/TMAmetabolism and other major methyl donors, betaine and choline. SAM, S-adenosylmethionine; SAH, S-adeno-
sylhomocysteine; THF, tetrahydrofolic acid; BHMT, betaine homocysteine S-methyltransferase.
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olism of trimethylamines. This cometabo-
lism is likely to be subject to high interindi-
vidual variations as it is expected that
the metabolic outcome of TMA consump-
tion or any of its precursors strongly
depends on the composition of the gut
microbiota. Although more research is
needed to characterize the micro-organ-
isms involved in these metabolic transfor-700 Cell Metabolism 20, November 4, 2014 ªmations, this study provides new insights
into our understanding of trimethylamine
cometabolism in the context of energy
homeostasis.REFERENCES
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